Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy.

@article{Tashima1999CerebrospinalFH,
  title={Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy.},
  author={Karen T. Tashima and Angela M. Caliendo and Mark Ahmad and Jenny M Gormley and William D. Fiske and James Matthew Brennan and Timothy P. Flanigan},
  journal={The Journal of infectious diseases},
  year={1999},
  volume={180 3},
  pages={862-4}
}
Efavirenz, a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase, is a promising addition to the antiretroviral armamentarium. Efavirenz levels and HIV-1 RNA levels were measured in cerebrospinal fluid (CSF) and plasma of 10 HIV-1-infected patients taking efavirenz, 600 mg daily, in combination with other antiretroviral medications. Efavirenz was detected in the CSF at a mean concentration of 35.1 nM (range, 6. 6-58.9 nM), which was above the IC95 for wild-type… CONTINUE READING

From This Paper

Topics from this paper.
31 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Similar Papers

Loading similar papers…